Subscribe Now
Rankings
Magazine
Newsletters
Podcasts
Video On Demand
Fortune Live Media
Fortune Connect
Fortune Education
Fortune Well
Fortune Crypto
Fortune Recommends
Rankings
See All Rankings
Fortune 500
Global 500
40 Under 40
GREAT PLACE TO WORK LISTS
Best MBA Programs
Magazine
April/May 2023
February/March 2023
December 2022/January 2023
October/November 2022
Newsletters
Podcasts
More
Video On Demand
Fortune Live Media
Fortune Connect
Fortune Education
Fortune Well
Fortune Crypto
Fortune Recommends
SEARCH
SEARCH
SIGN IN
Subscribe Now
John Lauerman
Health
Don’t toss those expired home COVID test kits. They may still be good after all
BY
Lindsey Rupp
,
John Lauerman
, and others
Health
A new batch of COVID pills are in focus as daily life reopens. Here’s how the treatments work—and how well
BY
Jason Gale
,
John Lauerman
, and others
Health
Catching the common cold can help fend off COVID, study finds
BY
Tim Loh
,
John Lauerman
, and others
Finance
Johnson & Johnson shares jump as company follows GE and Toshiba in decision to split business apart
BY
Riley Griffin
,
John Lauerman
, and others
Health
Merck says the U.S. will buy 1.4 million doses of its COVID-19 antiviral pill
BY
John Lauerman
and
Bloomberg
Health
FDA advisors unanimously back Johnson & Johnson COVID boosters for people 18 and older
BY
John Lauerman
and
Bloomberg
Health
What you need to know about severe reactions to COVID vaccines
BY
John Lauerman
,
Jason Gale
, and others
Health
What to know about delaying second COVID vaccine shots as countries grapple with limited supplies
BY
John Lauerman
,
Jason Gale
, and others
Health
Everything to know about allergic reactions to COVID vaccines
BY
John Lauerman
and
Bloomberg
Health
Pfizer to supply U.S. with 100 million more vaccine doses
BY
John Lauerman
,
Riley Griffin
, and others
Health
AstraZeneca acquires rare-disease specialist Alexion in $39 billion deal
BY
John Lauerman
,
James Paton
, and others
Health
Anthony Fauci tones down earlier criticism of U.K.’s Pfizer vaccine approval
BY
John Lauerman
,
Mike Dorning
, and others
Health
For AstraZeneca’s COVID vaccine, less may be more—and that’s puzzling researchers
BY
Angelica LaVito
,
John Lauerman
, and others
Health
U.S. government secures 100 million doses of Pfizer, BioNTech vaccine for $2 billion
BY
John Lauerman
and
Bloomberg
International
The earliest coronavirus vaccines may not protect you from getting infected
BY
John Lauerman
,
James Paton
, and others
Most Popular
Finance
The housing market is so broken that many 40- and 30-something millennials have no choice but to build homes in their...
BY
Jeff Kruth
,
Murali Paranandi
, and others
Features
Motorola ditched cell phones and found a lucrative second act. Now it’s one of tech’s biggest turnaround stories
BY
Stephen Gandel
Tech
Twitter cofounder Evan Williams says Elon Musk’s purchase of the company made him ‘sad’: ‘He’s brilliant. But no one’s...
BY
Chloe Taylor
Load More